To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer
Conditions
- Non-small Cell Lung Cancer
Interventions
- DRUG: Anlotinib
- DRUG: Placebo Capsule
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Collaborators